Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PHAR with free AI briefings, catalyst countdowns, and dilution alerts.

PHAR · Pharming Group N.V.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$189.6M Cash on Hand
CF+ Cash Runway
Follow PHAR by email Get an email when PHAR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PHAR, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-01-30 Joenja children with APDS sNDA 94%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What PHAR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Leniolisib
FDA approved Mar 2023 · Joenja
APDS Phase 3 · NCT05438407 Active not recruiting
CDZ173 Activated PI3Kdelta Syndrome (APDS); PASLI Disease Phase 2/3 · NCT02859727 Terminated
i.v. recombinant human C1 inhibitor Genetic Disorders Phase 2/3 · NCT00262288 Completed
C1 Esterase Inhibitor Recombinant Hereditary Angioedema Phase 2/3 · NCT00225147 Completed
Conestat Alfa Coronavirus Infections Phase 2 · NCT04414631 Terminated
KL1333 Primary Mitochondrial Disease Phase 2 · NCT05650229 Recruiting
NACL 0.9% Acute Ischemic Stroke Phase 2 · NCT05145283 Completed
Napazimone Mitochondrial Diseases Phase 2 · NCT07514338 Recruiting
recombinant C1 inhibitor Graft Rejection Phase 2 · NCT01035593 Withdrawn
Saline Acute Kidney Injury Phase 2 · NCT02869347 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PHAR holds $189.6M in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 15 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PHAR files for a raise →

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-09-11 Joenja sNDA -11.7% +3.8% -0.2%

Browse all historical PDUFA outcomes →

Get the full PHAR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHAR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.